Status:
COMPLETED
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Hematopoietic Cell Transplantation
Oncology
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hematopoietic cell transplantation (HCT) is the only curative treatment modality for many hematologic malignancies. Morbidity and mortality rates have declined drastically over the years, secondary to...
Detailed Description
The investigators hypothesize that the implementation of a pharmacist-driven precision medicine service guided by HCT clinical pharmacists and Specialty Pharmacy pharmacists using preemptive pharmacog...
Eligibility Criteria
Inclusion
- Written informed consent and HIPAA authorization for release of personal health information
- Age ≥ 18 years at the time of consent
- Scheduled HCT (allogeneic and autologous, any conditioning regimen) treatment for any malignant or non-malignant indications (i.e. aplastic anemia)
- Ability to read and understand English or Spanish
- Able to provide a buccal sample for DNA extraction and genotyping
Exclusion
- Psychiatric illness/social situations, or active/recent (within 30 days) history of elicit substance abuse that would limit compliance with study requirements as determined by the investigator
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 9 2023
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04727827
Start Date
February 1 2021
End Date
June 9 2023
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204